カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

レミケード（インフリキシマブ）薬の世界市場2022：ブランド医薬品、ジェネリック医薬品

■ 英語タイトル：Global Remicade (infliximab) Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
	■ 発行会社/調査会社：GlobalInfoResearch ■ 商品コード：GIR22DC3624 ■ 発行日：2023年1月 ■ 調査対象地域：グローバル ■ 産業分野：医療機器 ■ ページ数：90 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（注文後2-3日）

■ 販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,480 ⇒換算￥528,960	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,220 ⇒換算￥793,440	見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）	USD6,960 ⇒換算￥1,057,920	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[レミケード（インフリキシマブ）薬の世界市場2022：ブランド医薬品、ジェネリック医薬品]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

世界のレミケード（インフリキシマブ）薬市場レポートは、グローバル市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
Global Info Research社の最新のリサーチによると、世界のレミケード（インフリキシマブ）薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

レミケード（インフリキシマブ）薬市場はタイプとアプリケーションによって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメントは次をカバーします。
・ブランド医薬品、ジェネリック医薬品

アプリケーション別セグメントは次のように区分されます。
・クローン病、小児クローン病、潰瘍性大腸炎、小児潰瘍性大腸炎、その他

世界のレミケード（インフリキシマブ）薬市場の主要な市場プレーヤーは以下のとおりです。
・Janssen、Hospira、Celltrion Healthcare、Epirus Biopharmaceuticals、Samsung Bioepsis

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・欧州（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南米（ブラジル、アルゼンチン、コロンビア）
・中東/アフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査資料の内容は計15章あります。
・第1章では、レミケード（インフリキシマブ）薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なレミケード（インフリキシマブ）薬メーカーの企業概要、2019年～2022年までのレミケード（インフリキシマブ）薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なレミケード（インフリキシマブ）薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別レミケード（インフリキシマブ）薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのレミケード（インフリキシマブ）薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのレミケード（インフリキシマブ）薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびレミケード（インフリキシマブ）薬の産業チェーンを掲載しています。
・第13、14、15章では、レミケード（インフリキシマブ）薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
– レミケード（インフリキシマブ）薬の概要
– 種類別分析（2017年vs2021年vs2028年）：ブランド医薬品、ジェネリック医薬品
– 用途別分析（2017年vs2021年vs2028年）：クローン病、小児クローン病、潰瘍性大腸炎、小児潰瘍性大腸炎、その他
– 世界のレミケード（インフリキシマブ）薬市場規模・予測
– 世界のレミケード（インフリキシマブ）薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Janssen、Hospira、Celltrion Healthcare、Epirus Biopharmaceuticals、Samsung Bioepsis
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ブランド医薬品、ジェネリック医薬品
・用途別分析2017年-2028年：クローン病、小児クローン病、潰瘍性大腸炎、小児潰瘍性大腸炎、その他
・レミケード（インフリキシマブ）薬の北米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・レミケード（インフリキシマブ）薬のヨーロッパ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・レミケード（インフリキシマブ）薬のアジア市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・レミケード（インフリキシマブ）薬の南米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・レミケード（インフリキシマブ）薬の中東・アフリカ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Remicade (infliximab) Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Remicade (infliximab) Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Brands Drugs
1.2.3 Generic Drugs
1.3 Market Analysis by Application
1.3.1 Overview: Global Remicade (infliximab) Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Crohn’s Disease
1.3.3 Pediatric Crohn’s Disease
1.3.4 Ulcerative Colitis
1.3.5 Pediatric Ulcerative Colitis
1.3.6 Other
1.4 Global Remicade (infliximab) Drug Market Size & Forecast
1.4.1 Global Remicade (infliximab) Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Remicade (infliximab) Drug Sales in Volume (2017-2028)
1.4.3 Global Remicade (infliximab) Drug Price (2017-2028)
1.5 Global Remicade (infliximab) Drug Production Capacity Analysis
1.5.1 Global Remicade (infliximab) Drug Total Production Capacity (2017-2028)
1.5.2 Global Remicade (infliximab) Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Remicade (infliximab) Drug Market Drivers
1.6.2 Remicade (infliximab) Drug Market Restraints
1.6.3 Remicade (infliximab) Drug Trends Analysis
2 Manufacturers Profiles
2.1 Janssen
2.1.1 Janssen Details
2.1.2 Janssen Major Business
2.1.3 Janssen Remicade (infliximab) Drug Product and Services
2.1.4 Janssen Remicade (infliximab) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Hospira
2.2.1 Hospira Details
2.2.2 Hospira Major Business
2.2.3 Hospira Remicade (infliximab) Drug Product and Services
2.2.4 Hospira Remicade (infliximab) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Celltrion Healthcare
2.3.1 Celltrion Healthcare Details
2.3.2 Celltrion Healthcare Major Business
2.3.3 Celltrion Healthcare Remicade (infliximab) Drug Product and Services
2.3.4 Celltrion Healthcare Remicade (infliximab) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Epirus Biopharmaceuticals
2.4.1 Epirus Biopharmaceuticals Details
2.4.2 Epirus Biopharmaceuticals Major Business
2.4.3 Epirus Biopharmaceuticals Remicade (infliximab) Drug Product and Services
2.4.4 Epirus Biopharmaceuticals Remicade (infliximab) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Samsung Bioepsis
2.5.1 Samsung Bioepsis Details
2.5.2 Samsung Bioepsis Major Business
2.5.3 Samsung Bioepsis Remicade (infliximab) Drug Product and Services
2.5.4 Samsung Bioepsis Remicade (infliximab) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Remicade (infliximab) Drug Breakdown Data by Manufacturer
3.1 Global Remicade (infliximab) Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Remicade (infliximab) Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Remicade (infliximab) Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Remicade (infliximab) Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Remicade (infliximab) Drug Manufacturer Market Share in 2021
3.5 Global Remicade (infliximab) Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Remicade (infliximab) Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Remicade (infliximab) Drug Market Size by Region
4.1.1 Global Remicade (infliximab) Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Remicade (infliximab) Drug Revenue by Region (2017-2028)
4.2 North America Remicade (infliximab) Drug Revenue (2017-2028)
4.3 Europe Remicade (infliximab) Drug Revenue (2017-2028)
4.4 Asia-Pacific Remicade (infliximab) Drug Revenue (2017-2028)
4.5 South America Remicade (infliximab) Drug Revenue (2017-2028)
4.6 Middle East and Africa Remicade (infliximab) Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Remicade (infliximab) Drug Sales in Volume by Type (2017-2028)
5.2 Global Remicade (infliximab) Drug Revenue by Type (2017-2028)
5.3 Global Remicade (infliximab) Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Remicade (infliximab) Drug Sales in Volume by Application (2017-2028)
6.2 Global Remicade (infliximab) Drug Revenue by Application (2017-2028)
6.3 Global Remicade (infliximab) Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Remicade (infliximab) Drug Sales by Type (2017-2028)
7.2 North America Remicade (infliximab) Drug Sales by Application (2017-2028)
7.3 North America Remicade (infliximab) Drug Market Size by Country
7.3.1 North America Remicade (infliximab) Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Remicade (infliximab) Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Remicade (infliximab) Drug Sales by Type (2017-2028)
8.2 Europe Remicade (infliximab) Drug Sales by Application (2017-2028)
8.3 Europe Remicade (infliximab) Drug Market Size by Country
8.3.1 Europe Remicade (infliximab) Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Remicade (infliximab) Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Remicade (infliximab) Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Remicade (infliximab) Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Remicade (infliximab) Drug Market Size by Region
9.3.1 Asia-Pacific Remicade (infliximab) Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Remicade (infliximab) Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Remicade (infliximab) Drug Sales by Type (2017-2028)
10.2 South America Remicade (infliximab) Drug Sales by Application (2017-2028)
10.3 South America Remicade (infliximab) Drug Market Size by Country
10.3.1 South America Remicade (infliximab) Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Remicade (infliximab) Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Remicade (infliximab) Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Remicade (infliximab) Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Remicade (infliximab) Drug Market Size by Country
11.3.1 Middle East & Africa Remicade (infliximab) Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Remicade (infliximab) Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Remicade (infliximab) Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Remicade (infliximab) Drug
12.3 Remicade (infliximab) Drug Production Process
12.4 Remicade (infliximab) Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Remicade (infliximab) Drug Typical Distributors
13.3 Remicade (infliximab) Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Remicade (infliximab) Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Remicade (infliximab) Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Janssen Basic Information, Manufacturing Base and Competitors
Table 4. Janssen Major Business
Table 5. Janssen Remicade (infliximab) Drug Product and Services
Table 6. Janssen Remicade (infliximab) Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Hospira Basic Information, Manufacturing Base and Competitors
Table 8. Hospira Major Business
Table 9. Hospira Remicade (infliximab) Drug Product and Services
Table 10. Hospira Remicade (infliximab) Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Celltrion Healthcare Basic Information, Manufacturing Base and Competitors
Table 12. Celltrion Healthcare Major Business
Table 13. Celltrion Healthcare Remicade (infliximab) Drug Product and Services
Table 14. Celltrion Healthcare Remicade (infliximab) Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Epirus Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Epirus Biopharmaceuticals Major Business
Table 17. Epirus Biopharmaceuticals Remicade (infliximab) Drug Product and Services
Table 18. Epirus Biopharmaceuticals Remicade (infliximab) Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Samsung Bioepsis Basic Information, Manufacturing Base and Competitors
Table 20. Samsung Bioepsis Major Business
Table 21. Samsung Bioepsis Remicade (infliximab) Drug Product and Services
Table 22. Samsung Bioepsis Remicade (infliximab) Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Global Remicade (infliximab) Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 24. Global Remicade (infliximab) Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 25. Market Position of Manufacturers in Remicade (infliximab) Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 26. Global Remicade (infliximab) Drug Production Capacity by Company, (K Units): 2020 VS 2021
Table 27. Head Office and Remicade (infliximab) Drug Production Site of Key Manufacturer
Table 28. Remicade (infliximab) Drug New Entrant and Capacity Expansion Plans
Table 29. Remicade (infliximab) Drug Mergers & Acquisitions in the Past Five Years
Table 30. Global Remicade (infliximab) Drug Sales by Region (2017-2022) & (K Units)
Table 31. Global Remicade (infliximab) Drug Sales by Region (2023-2028) & (K Units)
Table 32. Global Remicade (infliximab) Drug Revenue by Region (2017-2022) & (USD Million)
Table 33. Global Remicade (infliximab) Drug Revenue by Region (2023-2028) & (USD Million)
Table 34. Global Remicade (infliximab) Drug Sales by Type (2017-2022) & (K Units)
Table 35. Global Remicade (infliximab) Drug Sales by Type (2023-2028) & (K Units)
Table 36. Global Remicade (infliximab) Drug Revenue by Type (2017-2022) & (USD Million)
Table 37. Global Remicade (infliximab) Drug Revenue by Type (2023-2028) & (USD Million)
Table 38. Global Remicade (infliximab) Drug Price by Type (2017-2022) & (USD/Unit)
Table 39. Global Remicade (infliximab) Drug Price by Type (2023-2028) & (USD/Unit)
Table 40. Global Remicade (infliximab) Drug Sales by Application (2017-2022) & (K Units)
Table 41. Global Remicade (infliximab) Drug Sales by Application (2023-2028) & (K Units)
Table 42. Global Remicade (infliximab) Drug Revenue by Application (2017-2022) & (USD Million)
Table 43. Global Remicade (infliximab) Drug Revenue by Application (2023-2028) & (USD Million)
Table 44. Global Remicade (infliximab) Drug Price by Application (2017-2022) & (USD/Unit)
Table 45. Global Remicade (infliximab) Drug Price by Application (2023-2028) & (USD/Unit)
Table 46. North America Remicade (infliximab) Drug Sales by Country (2017-2022) & (K Units)
Table 47. North America Remicade (infliximab) Drug Sales by Country (2023-2028) & (K Units)
Table 48. North America Remicade (infliximab) Drug Revenue by Country (2017-2022) & (USD Million)
Table 49. North America Remicade (infliximab) Drug Revenue by Country (2023-2028) & (USD Million)
Table 50. North America Remicade (infliximab) Drug Sales by Type (2017-2022) & (K Units)
Table 51. North America Remicade (infliximab) Drug Sales by Type (2023-2028) & (K Units)
Table 52. North America Remicade (infliximab) Drug Sales by Application (2017-2022) & (K Units)
Table 53. North America Remicade (infliximab) Drug Sales by Application (2023-2028) & (K Units)
Table 54. Europe Remicade (infliximab) Drug Sales by Country (2017-2022) & (K Units)
Table 55. Europe Remicade (infliximab) Drug Sales by Country (2023-2028) & (K Units)
Table 56. Europe Remicade (infliximab) Drug Revenue by Country (2017-2022) & (USD Million)
Table 57. Europe Remicade (infliximab) Drug Revenue by Country (2023-2028) & (USD Million)
Table 58. Europe Remicade (infliximab) Drug Sales by Type (2017-2022) & (K Units)
Table 59. Europe Remicade (infliximab) Drug Sales by Type (2023-2028) & (K Units)
Table 60. Europe Remicade (infliximab) Drug Sales by Application (2017-2022) & (K Units)
Table 61. Europe Remicade (infliximab) Drug Sales by Application (2023-2028) & (K Units)
Table 62. Asia-Pacific Remicade (infliximab) Drug Sales by Region (2017-2022) & (K Units)
Table 63. Asia-Pacific Remicade (infliximab) Drug Sales by Region (2023-2028) & (K Units)
Table 64. Asia-Pacific Remicade (infliximab) Drug Revenue by Region (2017-2022) & (USD Million)
Table 65. Asia-Pacific Remicade (infliximab) Drug Revenue by Region (2023-2028) & (USD Million)
Table 66. Asia-Pacific Remicade (infliximab) Drug Sales by Type (2017-2022) & (K Units)
Table 67. Asia-Pacific Remicade (infliximab) Drug Sales by Type (2023-2028) & (K Units)
Table 68. Asia-Pacific Remicade (infliximab) Drug Sales by Application (2017-2022) & (K Units)
Table 69. Asia-Pacific Remicade (infliximab) Drug Sales by Application (2023-2028) & (K Units)
Table 70. South America Remicade (infliximab) Drug Sales by Country (2017-2022) & (K Units)
Table 71. South America Remicade (infliximab) Drug Sales by Country (2023-2028) & (K Units)
Table 72. South America Remicade (infliximab) Drug Revenue by Country (2017-2022) & (USD Million)
Table 73. South America Remicade (infliximab) Drug Revenue by Country (2023-2028) & (USD Million)
Table 74. South America Remicade (infliximab) Drug Sales by Type (2017-2022) & (K Units)
Table 75. South America Remicade (infliximab) Drug Sales by Type (2023-2028) & (K Units)
Table 76. South America Remicade (infliximab) Drug Sales by Application (2017-2022) & (K Units)
Table 77. South America Remicade (infliximab) Drug Sales by Application (2023-2028) & (K Units)
Table 78. Middle East & Africa Remicade (infliximab) Drug Sales by Region (2017-2022) & (K Units)
Table 79. Middle East & Africa Remicade (infliximab) Drug Sales by Region (2023-2028) & (K Units)
Table 80. Middle East & Africa Remicade (infliximab) Drug Revenue by Region (2017-2022) & (USD Million)
Table 81. Middle East & Africa Remicade (infliximab) Drug Revenue by Region (2023-2028) & (USD Million)
Table 82. Middle East & Africa Remicade (infliximab) Drug Sales by Type (2017-2022) & (K Units)
Table 83. Middle East & Africa Remicade (infliximab) Drug Sales by Type (2023-2028) & (K Units)
Table 84. Middle East & Africa Remicade (infliximab) Drug Sales by Application (2017-2022) & (K Units)
Table 85. Middle East & Africa Remicade (infliximab) Drug Sales by Application (2023-2028) & (K Units)
Table 86. Remicade (infliximab) Drug Raw Material
Table 87. Key Manufacturers of Remicade (infliximab) Drug Raw Materials
Table 88. Direct Channel Pros & Cons
Table 89. Indirect Channel Pros & Cons
Table 90. Remicade (infliximab) Drug Typical Distributors
Table 91. Remicade (infliximab) Drug Typical Customers
List of Figures
Figure 1. Remicade (infliximab) Drug Picture
Figure 2. Global Remicade (infliximab) Drug Revenue Market Share by Type in 2021
Figure 3. Brands Drugs
Figure 4. Generic Drugs
Figure 5. Global Remicade (infliximab) Drug Revenue Market Share by Application in 2021
Figure 6. Crohn's Disease
Figure 7. Pediatric Crohn's Disease
Figure 8. Ulcerative Colitis
Figure 9. Pediatric Ulcerative Colitis
Figure 10. Other
Figure 11. Global Remicade (infliximab) Drug Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Remicade (infliximab) Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Remicade (infliximab) Drug Sales (2017-2028) & (K Units)
Figure 14. Global Remicade (infliximab) Drug Price (2017-2028) & (USD/Unit)
Figure 15. Global Remicade (infliximab) Drug Production Capacity (2017-2028) & (K Units)
Figure 16. Global Remicade (infliximab) Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Remicade (infliximab) Drug Market Drivers
Figure 18. Remicade (infliximab) Drug Market Restraints
Figure 19. Remicade (infliximab) Drug Market Trends
Figure 20. Global Remicade (infliximab) Drug Sales Market Share by Manufacturer in 2021
Figure 21. Global Remicade (infliximab) Drug Revenue Market Share by Manufacturer in 2021
Figure 22. Remicade (infliximab) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Remicade (infliximab) Drug Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Remicade (infliximab) Drug Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Remicade (infliximab) Drug Sales Market Share by Region (2017-2028)
Figure 26. Global Remicade (infliximab) Drug Revenue Market Share by Region (2017-2028)
Figure 27. North America Remicade (infliximab) Drug Revenue (2017-2028) & (USD Million)
Figure 28. Europe Remicade (infliximab) Drug Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Remicade (infliximab) Drug Revenue (2017-2028) & (USD Million)
Figure 30. South America Remicade (infliximab) Drug Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Remicade (infliximab) Drug Revenue (2017-2028) & (USD Million)
Figure 32. Global Remicade (infliximab) Drug Sales Market Share by Type (2017-2028)
Figure 33. Global Remicade (infliximab) Drug Revenue Market Share by Type (2017-2028)
Figure 34. Global Remicade (infliximab) Drug Price by Type (2017-2028) & (USD/Unit)
Figure 35. Global Remicade (infliximab) Drug Sales Market Share by Application (2017-2028)
Figure 36. Global Remicade (infliximab) Drug Revenue Market Share by Application (2017-2028)
Figure 37. Global Remicade (infliximab) Drug Price by Application (2017-2028) & (USD/Unit)
Figure 38. North America Remicade (infliximab) Drug Sales Market Share by Type (2017-2028)
Figure 39. North America Remicade (infliximab) Drug Sales Market Share by Application (2017-2028)
Figure 40. North America Remicade (infliximab) Drug Sales Market Share by Country (2017-2028)
Figure 41. North America Remicade (infliximab) Drug Revenue Market Share by Country (2017-2028)
Figure 42. United States Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Remicade (infliximab) Drug Sales Market Share by Type (2017-2028)
Figure 46. Europe Remicade (infliximab) Drug Sales Market Share by Application (2017-2028)
Figure 47. Europe Remicade (infliximab) Drug Sales Market Share by Country (2017-2028)
Figure 48. Europe Remicade (infliximab) Drug Revenue Market Share by Country (2017-2028)
Figure 49. Germany Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Remicade (infliximab) Drug Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Remicade (infliximab) Drug Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Remicade (infliximab) Drug Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Remicade (infliximab) Drug Revenue Market Share by Region (2017-2028)
Figure 58. China Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Remicade (infliximab) Drug Sales Market Share by Type (2017-2028)
Figure 65. South America Remicade (infliximab) Drug Sales Market Share by Application (2017-2028)
Figure 66. South America Remicade (infliximab) Drug Sales Market Share by Country (2017-2028)
Figure 67. South America Remicade (infliximab) Drug Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Remicade (infliximab) Drug Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Remicade (infliximab) Drug Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Remicade (infliximab) Drug Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Remicade (infliximab) Drug Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Remicade (infliximab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Remicade (infliximab) Drug in 2021
Figure 79. Manufacturing Process Analysis of Remicade (infliximab) Drug
Figure 80. Remicade (infliximab) Drug Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

レミケード（インフリキシマブ）薬の世界市場2022：ブランド医薬品、ジェネリック医薬品

グローバル市場調査会社